No FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) has ever existed. For the 40,000 Americans with this rare kidney disease—which drives half to kidney failure within a decade—the only options have been off-label immunosuppressants with mixed results.
On January 13, 2026, approval was expected. Instead, the FDA extended its review by three months, requesting more data on clinical benefit. The announcement triggered a 33% intraday stock plunge and shareholder investigations; two weeks later, CEO Eric Dube sold $1.56 million in company stock, drawing scrutiny for the timing.
The delay centers on a fundamental question: whether reducing protein in urine (proteinuria) actually prevents kidney failure. Sparsentan cut proteinuria by 50% in trials but failed to slow the rate of kidney function decline—the traditional standard for kidney drugs. The April 13, 2026 decision will determine if proteinuria reduction justifies approval; approval would validate a faster pathway for future kidney drugs, while rejection could slow drug development for rare diseases.
Travere's market capitalization fell from $3.12B to $2.59B between mid-December 2025 and mid-January 2026, reflecting investor concerns about FDA approval prospects.
Voices
Curated perspectives — historical figures and your fellow readers.
Ever wondered what historical figures would say about today's headlines?
Sign up to generate historical perspectives on this story.
17 events
Latest: January 27th, 2026 · 4 months ago
Showing 8 of 17
JK to step
Tap a bar to jump to that date
Jump to
January 2026
CEO Sells $1.56 Million in Company Stock
LatestCorporate
Eric Dube sold 51,865 shares at $30.10 per share, totaling $1,561,136.50. Following the transaction, the CEO directly owned 419,173 shares valued at approximately $12.6 million. The sale occurred two weeks after FDA review extension announcement and amid ongoing shareholder investigations.
Robbins Geller Launches Investigation
Legal
Law firm Robbins Geller Rudman & Dowd LLP announces investigation into potential securities law violations, examining whether Travere and executives made materially false or misleading statements regarding the company's business operations.
Shareholder Investigations Announced
Legal
Multiple law firms including Block & Leviton and Holzer & Holzer announce investigations into potential securities law violations related to disclosure of FDA review extension risk.
Bank of America Lowers Price Target
Market
Bank of America reduces price target to $43 from $47 following FDA review extension. Other analysts including Wedbush and Guggenheim maintain Buy ratings despite the setback.
FDA Extends Review by Three Months
Regulatory
FDA classifies Travere's responses to data requests as a Major Amendment, extending PDUFA date to April 13, 2026. No safety or manufacturing concerns cited.
Trading Halted Amid 33% Intraday Plunge
Market
TVTX trading was halted after shares fell more than 30% intraday following FDA extension announcement. Stock closed down approximately 20%. Analysts note heavy put option activity with 16,137 puts traded, a 694% increase versus typical volume.
Analyst Reactions Split on Approval Outlook
Market
Stifel maintains Hold rating with $31 price target, citing concerns about approvability based on failed eGFR endpoint and warning of 'low-teens' stock price if Complete Response Letter issued. Canaccord Genuity maintains Buy rating, providing counterbalance to negative sentiment.
CEO Presents at J.P. Morgan Healthcare Conference
Corporate
Eric Dube presents company update at 44th Annual J.P. Morgan Healthcare Conference, reporting $410 million in U.S. net product sales for fiscal year 2025 and $323 million in cash reserves. Presentation occurs one day before FDA extension announcement.
September 2025
FDA Cancels Advisory Committee
Regulatory
FDA determines advisory committee review is no longer necessary for sparsentan FSGS application.
May 2025
FDA Accepts FSGS Application
Regulatory
FDA accepts sparsentan sNDA for traditional approval in FSGS with original PDUFA date of January 13, 2026.
October 2024
FDA Holds FSGS Endpoint Workshop
Regulatory
FDA convenes scientific workshop to discuss proteinuria and GFR as clinical trial endpoints specifically for FSGS drug development.
September 2024
Full IgA Nephropathy Approval Granted
Regulatory
FDA converts sparsentan's accelerated approval to traditional approval based on confirmatory two-year kidney function data from PROTECT trial.
November 2023
DUPLEX Primary Endpoint Misses
Clinical Trial
Two-year results show sparsentan failed to significantly slow eGFR decline (the primary endpoint) compared to irbesartan, despite achieving greater proteinuria reduction.
February 2023
FDA Grants Accelerated Approval for IgA Nephropathy
Regulatory
Sparsentan receives accelerated approval for reducing proteinuria in IgA nephropathy, becoming the first non-immunosuppressive treatment for this related kidney disease.
September 2022
36-Week Interim Results Show Proteinuria Benefit
Clinical Trial
DUPLEX interim analysis demonstrates sparsentan achieves statistically significant proteinuria reduction at 36 weeks compared to irbesartan.
November 2020
DUPLEX Enrollment Complete
Clinical Trial
Travere announces completion of patient enrollment with 371 patients randomized across study sites worldwide.
April 2018
DUPLEX Trial Enrollment Begins
Clinical Trial
Travere initiates enrollment in the Phase 3 DUPLEX study, comparing sparsentan to irbesartan in patients with biopsy-proven FSGS. The trial would become the largest interventional study in FSGS history.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
December 2021 - December 2023
Tarpeyo IgA Nephropathy Approval (2021-2023)
Calliditas Therapeutics' Tarpeyo (budesonide) became the first drug approved for IgA nephropathy in December 2021 under accelerated approval, based solely on proteinuria reduction. The FDA required confirmatory data showing kidney function benefit.
Then
Patients gained access to first indicated treatment while long-term data collection continued.
Now
Two-year data showed 50% less kidney function decline versus placebo. FDA granted full approval December 2023, validating the surrogate endpoint approach.
Why this matters now
Demonstrates FDA willingness to accept proteinuria as a pathway to accelerated approval in rare kidney disease, though FSGS differs in that sparsentan is seeking traditional (not accelerated) approval.
2 of 3
September 2016
Eteplirsen Duchenne Approval Controversy (2016)
FDA granted accelerated approval to eteplirsen for Duchenne muscular dystrophy based on a tiny increase in dystrophin protein (0.28% of normal levels) in just 12 patients. An advisory committee voted against approval. Two FDA reviewers resigned in protest.
Then
CDER director Janet Woodcock overruled FDA scientific staff to grant approval. Patients gained access to treatment priced at $300,000 annually.
Now
As of 2025, confirmatory trials remain incomplete. FDA approved three more DMD drugs using the same surrogate endpoint. The case became emblematic of tension between patient access and evidence standards.
Why this matters now
Illustrates the stakes when surrogate endpoints lack clear connection to clinical outcomes. Sparsentan's situation differs: proteinuria-to-kidney-failure link is better established, but the primary eGFR endpoint failure raises similar questions about evidence thresholds.
3 of 3
December 2022
FDA Accelerated Approval Reforms (2022)
Congress passed reforms requiring drug companies to complete confirmatory trials more quickly and giving FDA clearer authority to withdraw accelerated approvals when trials fail or aren't completed. The FDA also began withdrawing approvals for cancer drugs that failed to confirm benefit.
Then
Multiple accelerated approvals were voluntarily withdrawn by manufacturers when confirmatory trials failed.
Now
FDA established stricter standards for surrogate endpoints and confirmatory trial timelines, raising the bar for new accelerated approvals.
Why this matters now
Creates context for FDA's careful approach to sparsentan FSGS approval. The agency faces pressure to ensure surrogate endpoints truly predict clinical benefit before granting approval, even as patients await treatment.
